Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7196-7206, August 2026.ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise +10 more
wiley +1 more source
Related searches:
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #tirzepatide
+45 more sources
Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection. [PDF]
Pharmaceuticals (Basel)Shin MH +6 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6810-6823, August 2026.ABSTRACT Aims Calorie restriction (CR) reduces both fat mass and fat‐free mass (FFM), particularly skeletal muscle mass (SMM), which is essential for cardiometabolic health and preventing frailty. This study compares CR alone versus CR plus exercise (EX) on FFM and SMM in overweight/obese patients and examines the effects of different training modes ...
Magdalena Deller +3 more
wiley +1 more source
Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification? [PDF]
Life (Basel)Mihălțan FD, Borcea CI, Constantin AA.
europepmc +1 more source
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6482-6508, August 2026.ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan +5 more
wiley +1 more source
Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. [PDF]
Am J Case RepChakrabarti MP, Han S, Campbell NM.
europepmc +1 more source
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano +4 more
wiley +1 more source
GIP/GLP-1 DUAL AGONIST TIRZEPATIDE AMELIORATES RENAL ISCHEMIA/REPERFUSION DAMAGE IN RATS
Objective: Renal Ischemia/Reperfusion Injury (RIRI) initiates a cascade of deleterious events resulting in acute kidney injury with high mortality rates.
ALKHAFAJI, GHADA A., JANABI, ALI M.
core
Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System. [PDF]
CureusMakhmutov A, Qureshi F.
europepmc +1 more source